Catalent (CTLT) has experienced significant recent activity, including the closing of a $16.5 billion buyout by Novo Holdings. The deal was approved by the European Commission and overcame other significant regulatory hurdles. Despite a stellar revenue performance ahead of the deal's completion, CTLT shares experienced some volatility due to potential hindrances to the buyout. US Senator Elizabeth Warren called for the deal to be scrutinized, while other moves by the company included the sale of its New Jersey facility and a $25 million expansion at its Clinical Supply Facility in Germany. Concerns arose around Novo Holdings' acquisition after concerns were raised regarding control lapses at a Catalent plant. Despite these issues, Catalent continues its growth trajectory with plans to extend leadership in the nutraceuticals market with a $1 Billion Acquisition of Bettera.
Catalent CTLT News Analytics from Tue, 19 Sep 2017 07:00:00 GMT to Thu, 20 Feb 2025 08:00:00 GMT -
Rating 6
- Innovation 4
- Information 8
- Rumor 2
